Finding treatments for advanced stage cancer isn’t easy. Therefore, early detection methods are paramount in the fight against the disease. Motivated by the opportunity to intervene as early as possible in the course of cancer, Dr. Muneesh Tewari, a Univ. of Michigan researcher, has been studying the diagnostic potential of blood-based biomarkers.
Beating cancer is all about early detection, and new research from the Univ. of South Carolina is another step forward in catching the disease early. A team of chemists is reporting a new way to detect just a few lurking tumor cells, which can be outnumbered a billion to one in the bloodstream by healthy cells.
A diverse team of scientists from Univ. of California, Los Angeles' Jonsson Comprehensive Cancer Center has developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects. The drug works by blocking two important metabolic pathways that the leukemia cells need to grow and spread.
If a driver is traveling to New York City, I-95 might be their route of choice. But they could also take I-78, I-87 or any number of alternate routes. Most cancers begin similarly, with many possible routes to the same disease. A new study found evidence that assessing the route to cancer on a case-by-case basis might make more sense than basing a patient’s cancer treatment on commonly disrupted genes and pathways.
Women with estrogen-responsive breast cancer who consume soy protein supplements containing isoflavones to alleviate the side effects of menopause may be accelerating progression of their cancer, changing it from a treatable subtype to a more aggressive, less treatable form of the disease, new research suggests.
The Food and Drug Administration on Wednesday approved a cancer drug from Pharmacyclics and Janssen Biotech Inc. for a new use against a rare blood and bone marrow disease. The agency said it approved Imbruvica for patients with chronic lymphocytic leukemia who have already tried at least one other therapy.
A Canadian study that many experts say has major flaws has revived a debate about the value of mammograms. The study suggests that these screening x-rays do not lower the risk of dying of breast cancer while finding many tumors that do not need treatment. The study gives longer follow-up on nearly 90,000 women who were given either a breast exam by a nurse to check for lumps plus a mammogram or the breast exam alone.
In the U.S. about 12,500 women are diagnosed with cervical cancer a year. Out of these women, about 4,500 progress into invasive cervical cancer or the end stage of the disease. This leaves about 8,000 women a year in the U.S. that are cured through existing standard of care treatment: surgery or chemotherapy/radiation. However, chemotherapy/radiation have terrible side effects in some cases.
Pancreatic cancer is a particularly devastating disease. At least 94% of patients will die within five years, and in 2013 it was ranked as one of the top 10 deadliest cancers. Routine screenings for breast, colon and lung cancers have improved treatment and outcomes for patients with these diseases. But because little is known about how pancreatic cancer behaves, patients often receive a diagnosis when it’s already too late.
Nearly 70% of patients with advanced breast cancer experience skeletal metastasis, in which cancer cells migrate from a primary tumor into bone. While scientists are attempting to better understand metastasis in general, not much is known about how and why certain cancers spread to specific organs. Now researchers have developed a 3-D microfluidic platform that mimics the spread of breast cancer cells into a bone-like environment.
Maybe you’ve seen the movies or played with toy Transformers, those shape-shifting machines that morph in response to whatever challenge they face. It turns out that DNA-repair machines in your cells use a similar approach to fight cancer and other diseases, according to research led by scientists from Lawrence Berkeley National Laboratory.
Researchers at Oregon State Univ. have discovered a genetic function that helps one of the most important “tumor suppressor” genes to do its job and prevent cancer. Finding ways to maintain or increase the effectiveness of this gene—called Grp1-associated scaffold protein, or Grasp—could offer an important new avenue for human cancer therapies, scientists said.
A new report says childhood cancer cases continue to increase, but death rates have fallen by half. The American Cancer Society report—released Friday—is being called one of the most comprehensive looks at the types of cancer that most commonly affect children and adolescents.
Cancer drugs that recruit antibodies from the body’s own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return. A new study from Massachusetts Institute of Technology reveals a way to combat these recurrent tumors with a drug that makes them more vulnerable to the antibody treatment.
One of every 10 clinical trials for adults with cancer ends prematurely because researchers can't get enough people to test new treatments, scientists report. The surprisingly high rate reveals not just the scope and cost of wasted opportunities that deprive patients of potential advances, but also the extent of barriers such as money, logistics and even the mistaken fear that people won't get the best care if they join these experiments.
Using a novel high-throughput screening process, scientists have, for the first time, identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma. Glaucoma is a group of diseases that can damage the eye’s optic nerve and cause vision loss and blindness. Elevated eye pressure is the main risk factor for optic nerve damage.
Biomedical engineer Lihong Wang and researchers in his laboratory work with lasers used in photoacoustic imaging for early cancer detection and a close look at biological tissue. But sometimes there are limitations to what they can do; and as engineers, they work to find a way around those limitations. The team found a novel way to use an otherwise unwanted side effect of the lasers they use—the photo bleaching effect—to their advantage.
A new porous structure under development in German possesses essential properties of natural bone marrow and can be used for the reproduction of stem cells in the laboratory. The specific reproduction of these hematopoietic cells outside the body might facilitate new therapies for leukemia in a few years.
Researchers at the Univ. of Louisville have confirmed that using the heat profile from a person’s blood, called a plasma thermogram, can serve as an indicator for the presence or absence of cervical cancer, including the stage of cancer. To generate a plasma thermogram, a blood plasma sample is melted, producing a unique signature indicating a person’s health status.
A new method for analyzing biological samples' chemical makeup is set to transform the way medical scientists examine diseased tissue. When tests are carried out on a patient’s tissue today, such as to look for cancer, the test has to be interpreted by a histology specialist, and can take weeks to obtain a full result. Mass spectrometry imaging uses technologies that reveal how chemical components are distributed in a tissue sample.
Although complications from surgical care for cancer patients may seem infrequent, the costs associated with such outcomes are extremely high, according to researchers from Rice Univ.’s Baker Institute for Public Policy and the Univ. of Texas MD Anderson Cancer Center.
Researchers have developed a technique for creating nanoparticles that carry two different cancer-killing drugs into the body and deliver those drugs to separate parts of the cancer cell where they will be most effective. The technique was developed by researchers at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill.
A novel breast cancer therapy partially reverses the cancerous state in cultured breast tumor cells and prevents cancer development in mice, and it could one day provide a new way to treat early stages of the disease without resorting to surgery, chemotherapy or radiation, a multi-institutional team led by researchers from the Wyss Institute of Biologically Inspired Engineering at Harvard Univ. reported.
Metabolism was lost in the shadows of cancer research for decades but has recently been reclaiming some of the spotlight. Now, Mina Bissell, distinguished scientist with Lawrence Berkeley National Laboratory’s Life Sciences Div. and a leading authority on breast cancer, has shown that aerobic glycolysis is not the consequence of the cancerous activity of malignant cells but is itself a cancerous event.
A novel and faster way to test cancer drugs has yielded its first big result: An experimental medicine that shows promise against a hard-to-treat form of breast cancer. The method involves studying drugs in small groups of people to quickly separate winners from duds. Bringing a new cancer drug to market usually takes more than a decade and tests in thousands of patients, and costs more than $1 billion.